← All trials
NCT04565717
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 9, 2020
- Primary completion
- May 31, 2023
- Completion date
- Jun 30, 2023
- First posted
- Sep 25, 2020
- Last posted
- Dec 16, 2020
- Enrollment
- 128
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Alnylam PharmaceuticalsLead sponsor
- Alnylam PharmaceuticalsStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.